Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry.
C3
Cell imaging
Complement system
Endothelial cells
Flow cytometry
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
23
6
2021
Statut:
ppublish
Résumé
The three pathways of the complement system converge toward the cleavage of the central complement component C3 into its activated fragments, with C3b being able to bind covalently to the activating surface. The endothelial cells are among the major targets for complement attack in pathological conditions, as the atypical hemolytic uremic syndrome. Therefore, study of complement C3 deposition on endothelial cells by flow cytometry is a sensitive test to measure complement activation. This test can be used as a research or clinical tool to test complement activation induced by patients' sera or to test the functional consequences of newly discovered complement mutations as well as different triggers of endothelial cells injury.
Identifiants
pubmed: 33847934
doi: 10.1007/978-1-0716-1016-9_9
doi:
Substances chimiques
C3 protein, human
0
Complement C3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97-105Références
Merle NS, Church SE, Fremeaux-Bacchi V et al (2015) Complement system part I—molecular mechanisms of activation and regulation. Front Immunol 6:262. https://doi.org/10.3389/fimmu.2015.00262
doi: 10.3389/fimmu.2015.00262
pubmed: 26082779
pmcid: 4451739
Merle NS, Paule R, Leon J et al (2019) P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proc Natl Acad Sci U S A 116(13):6280–6285. https://doi.org/10.1073/pnas.1814797116
doi: 10.1073/pnas.1814797116
pubmed: 30850533
pmcid: 6442544
Roumenina LT, Chadebech P, Bodivit G et al (2020) Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 95(5):456–464. https://doi.org/10.1002/ajh.25742
doi: 10.1002/ajh.25742
pubmed: 31990387
Fakhouri F, Zuber J, Fremeaux-Bacchi V et al (2017) Haemolytic uraemic syndrome. Lancet (London, England) 390(10095):681–696. https://doi.org/10.1016/s0140-6736(17)30062-4
doi: 10.1016/s0140-6736(17)30062-4
Roumenina LT, Jablonski M, Hue C et al (2009) Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114(13):2837–2845. https://doi.org/10.1182/blood-2009-01-197640
doi: 10.1182/blood-2009-01-197640
pubmed: 19584399
Roumenina LT, Frimat M, Miller EC et al (2012) A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119(18):4182–4191. https://doi.org/10.1182/blood-2011-10-383281
doi: 10.1182/blood-2011-10-383281
pubmed: 22246034
pmcid: 3359738
Marinozzi MC, Vergoz L, Rybkine T et al (2014) Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol 25(9):2053–2065. https://doi.org/10.1681/asn.2013070796
doi: 10.1681/asn.2013070796
pubmed: 24652797
pmcid: 4147975
Chauvet S, Roumenina LT, Bruneau S et al (2016) A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H. J Am Soc Nephrol 27(6):1665–1677. https://doi.org/10.1681/asn.2015040348
doi: 10.1681/asn.2015040348
pubmed: 26471127
Riedl M, Fakhouri F, Le Quintrec M et al (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40(4):444–464. https://doi.org/10.1055/s-0034-1376153
doi: 10.1055/s-0034-1376153
pubmed: 24911558
Frimat M, Tabarin F, Dimitrov JD et al (2013) Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122(2):282–292. https://doi.org/10.1182/blood-2013-03-489245
doi: 10.1182/blood-2013-03-489245
pubmed: 23692858
May O, Merle NS, Grunenwald A et al (2018) Heme drives susceptibility of glomerular endothelium to complement Overactivation due to inefficient upregulation of Heme Oxygenase-1. Front Immunol 9:3008. https://doi.org/10.3389/fimmu.2018.03008
doi: 10.3389/fimmu.2018.03008
pubmed: 30619356
pmcid: 6306430
Noris M, Galbusera M, Gastoldi S et al (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124(11):1715–1726. https://doi.org/10.1182/blood-2014-02-558296
doi: 10.1182/blood-2014-02-558296
pubmed: 25037630
pmcid: 4162105
Galbusera M, Noris M, Gastoldi S et al (2019) An ex vivo test of complement activation on endothelium for individualized Eculizumab therapy in hemolytic uremic syndrome. Am J Kidney Dis 74(1):56–72. https://doi.org/10.1053/j.ajkd.2018.11.012
doi: 10.1053/j.ajkd.2018.11.012
pubmed: 30851964
Wiatr M, Merle NS, Boudhabhay I et al (2019) Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Mol Immunol 111:205–208. https://doi.org/10.1016/j.molimm.2019.04.020
doi: 10.1016/j.molimm.2019.04.020
pubmed: 31078967
pmcid: 6560225
Timmermans S, Abdul-Hamid MA, Potjewijd J et al (2018) C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic Microangiopathy and severe hypertension. J Am Soc Nephrol 29(8):2234–2243. https://doi.org/10.1681/asn.2018020184
doi: 10.1681/asn.2018020184
pubmed: 29858281
pmcid: 6065094
Palomo M et al (2019) Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol. PMID: 31694864
Ades EW, Candal FJ, Swerlick RA et al (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99(6):683–690. https://doi.org/10.1111/1523-1747.ep12613748
doi: 10.1111/1523-1747.ep12613748
pubmed: 1361507
Satchell SC, Tasman CH, Singh A et al (2006) Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 69(9):1633–1640. https://doi.org/10.1038/sj.ki.5000277
doi: 10.1038/sj.ki.5000277
pubmed: 16557232